- Home
- IMRN vs PMCB Comparison
IMRN vs PMCB Comparison
Compare IMRN & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- PMCB
- Stock Information
- Founded
- IMRN 1994
- PMCB 1996
- Country
- IMRN Australia
- PMCB United States
- Employees
- IMRN N/A
- PMCB N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMRN Health Care
- PMCB Health Care
- Exchange
- IMRN Nasdaq
- PMCB Nasdaq
- Market Cap
- IMRN 15.0M
- PMCB 13.9M
- IPO Year
- IMRN N/A
- PMCB N/A
- Fundamental
- Price
- IMRN $1.81
- PMCB $1.64
- Analyst Decision
- IMRN Strong Buy
- PMCB
- Analyst Count
- IMRN 1
- PMCB 0
- Target Price
- IMRN $5.00
- PMCB N/A
- AVG Volume (30 Days)
- IMRN 6.2K
- PMCB 57.4K
- Earning Date
- IMRN 11-26-2024
- PMCB 12-13-2024
- Dividend Yield
- IMRN N/A
- PMCB N/A
- EPS Growth
- IMRN N/A
- PMCB N/A
- EPS
- IMRN N/A
- PMCB 0.54
- Revenue
- IMRN $3,271,194.00
- PMCB N/A
- Revenue This Year
- IMRN N/A
- PMCB N/A
- Revenue Next Year
- IMRN N/A
- PMCB N/A
- P/E Ratio
- IMRN N/A
- PMCB $3.06
- Revenue Growth
- IMRN 171.67
- PMCB N/A
- 52 Week Low
- IMRN $1.59
- PMCB $1.39
- 52 Week High
- IMRN $5.96
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- IMRN 35.96
- PMCB 40.27
- Support Level
- IMRN $1.73
- PMCB $1.72
- Resistance Level
- IMRN $1.99
- PMCB $1.94
- Average True Range (ATR)
- IMRN 0.12
- PMCB 0.17
- MACD
- IMRN 0.02
- PMCB -0.01
- Stochastic Oscillator
- IMRN 20.42
- PMCB 9.27
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.